Carotid Plaque Regression With Statin Treatment Assessed by High Field Magnetic Resonance Imaging (MRI)
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Short Term Carotid Plaque Regression in Patients With Atherosclerotic Disease Taking Statins Assessed by High Field MRI|
- Change in carotid artery plaque volume assessed by carotid MRI at 6 months [ Time Frame: 6 months ] [ Designated as safety issue: No ]
- Change in carotid intima media thickness on ultrasound at 6 months [ Time Frame: 6 months ] [ Designated as safety issue: No ]
- Change in plaque composition by carotid MRI at 6 months [ Time Frame: 6 months ] [ Designated as safety issue: No ]
- Change in inflammatory markers at 6 months [ Time Frame: 6 months ] [ Designated as safety issue: No ]
- Change in regional wall shear stress in the carotid artery [ Time Frame: 6 months ] [ Designated as safety issue: No ]
|Study Start Date:||August 2006|
|Study Completion Date:||February 2009|
|Primary Completion Date:||February 2009 (Final data collection date for primary outcome measure)|
Patients presenting with symptoms of coronary artery disease or stroke/suspected stroke, with carotid plaque > 1.1 mm, and whose statin dose is increased to moderate to high dose by their clinicians.
Patients presenting with symptoms due to coronary artery disease or stroke/suspected stroke, with carotid plaque > 1.1 mm, on no statins or whose statin dose was unchanged by their clinicians.
Atherosclerotic vascular disease is the leading cause of death in the United States. Atherosclerosis develops with increasing plaque burden and eccentric arterial wall expansion or remodeling, later leading to luminal obstruction. More than 90% of patients with CAD have carotid plaques. Statins have been shown to cause plaque regression in the carotid and coronary arteries. However, there is ongoing controversy about how low the target LDL should be in atherosclerotic patients. The benefits of aggressive LDL lowering with higher statin doses are counterbalanced by the potential for liver and muscle toxicity. High field (3 Tesla) MRI is a promising new modality for measuring plaque volume with high spatial resolution. It is not clear whether increasing statin dose will lead to plaque volume reduction in the short-term (6 months) that can be measured by this new modality.
The primary aim of the study is to determine if LDL lowering using statins in vascular disease patients with carotid plaque will be associated with measurable reduction in carotid plaque volume in the short term (6 months) using 3T MRI.
The four secondary aims of the study are as follows:
To compare the short term carotid plaque volume change using high field MRI in vascular disease patients whose statin dose was increased (dose increased) versus those whose statin dose was maintained (dose maintained).
To determine if increasing statin dose in patients with carotid plaque will lead to measurable change in carotid plaque composition in the short term (6 months) using 3T MRI.
To compare the carotid plaque volume change using 3T MRI with change in plaque burden score using carotid ultrasound .
To determine the relationship between change in plaque volume with change in lipid levels (total cholesterol, LDL, HDL) and change in inflammatory markers (cytokines, high sensitivity CRP).
The study is significant because it will provide insight into optimal statin treatment for atherosclerotic disease. It will also test a new modality for measurement of plaque burden. A reliable and sensitive test with high spatial resolution that accurately measures change in plaque volume will be helpful in assessing response to treatment and as a tool for future clinical trials in assessing efficacy of new treatment modalities that may reduce the need for expensive, long term studies that rely on clinical events for outcome measurement.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00388843
|United States, Wisconsin|
|Medical College of Wisconsin/Froedtert Memorial and Lutheran Hospital|
|Milwaukee, Wisconsin, United States, 53226|
|Principal Investigator:||Raymond Migrino, MD||Medical College of Wisconsin|